Group 1 - The company reported a significant increase in revenue and net profit for Q1 2025, with operating income reaching RMB 5.382 billion, up 49.04% year-on-year, and net profit attributable to shareholders amounting to RMB 1.436 billion, an increase of 62.08% compared to the same period last year [3] - The growth in performance is primarily attributed to increased income from proprietary trading and wealth management businesses [3] - As of the end of Q1 2025, the company's total assets were RMB 413.459 billion, a decrease of 1.02% from the end of the previous year, while equity attributable to shareholders increased by 1.54% to RMB 82.653 billion [4] Group 2 - The company emphasizes a focus on high-quality development and optimizing asset allocation to seize market opportunities [3] - The reported financial data is preliminary and has not been audited, with final figures to be disclosed in the official Q1 report [5]

Financial Performance Summary - In Q1 2025, the company reported significant improvements in its operational capacity and service capabilities, driven by an upgraded fleet structure and enhanced customer service [1] - The company expanded its market presence by launching new direct shipping routes, including Southeast Africa and Mediterranean automobile shipping services, which contributed to a solid foundation for operational efficiency [1] - Core cargo transportation volumes, including pulp, vehicles, wind power, and engineering equipment, experienced year-on-year growth, further supporting the company's performance in the first quarter [1] Revenue and Asset Management - The company reported a decrease in asset disposal income compared to the same period last year, where it recorded a gain of 43.82 million yuan from the disposal of old vessels; no such income was reported in the current period [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 2024年度業績快報公告 上海昊海生物科技股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據 《證券及期貨條例》（香港法例第571章）第XIVA部及《香港聯合交易所有限公司證 券上市規則》第13.09及13.10B條的要求發佈本公告，旨在向本公司股東及公眾人 士提供本公司的財務資料。本公告亦同時在上海證券交易所網站發佈。 本公告所載本集團按照中國企業會計準則編製的截至2024年12月31日止年度（「報 告期」）主要財務數據為初步核算未經核數師審計的數據。本集團報告期的具體財 務數據及經營業績將以本公司截至2024年12月31日止年度經審核之業績公告及本 公司2024年度報告所披露者為準。提請本公司潛在 ...